South Korea · Health Care · KRW (Millions) · Annual
Key financials
KRW|Millions
ROE
-31.49%
2025 (actual)
ROA
-24.15%
2025 (actual)
Gross Margin
100%
2025 (actual)
Net Margin
-548.09%
2025 (actual)
Total Assets
₩97,539.47M
2025 (actual)
Net Income
-₩23,554.58M
2025 (actual)
Valuation
₩4,021,220.69M
2026 (forecast)
Stock Price
₩91,800
Historical & projected performance
KRW|Millions
Reported figures and Equlion model projections for the next 5 years.
ROE
+168.1 pt
Company
ROA
+13.2 pt
Company
Gross Margin
+0 pt
Company
Sector average
Total Assets
+459.3%
Company
Sector average
Net Income
-146.1%
Company
Sector average (own scale)
Valuation
+182.5%
Company
Sector average (own scale)
Stock Price
+182.5%
Company
Sector average
Amounts in KRW (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for D&D Pharmatech? It covers the balance sheet, income statement, cash flow and Equlion model projections.